After putting up evidence to show that the liver toxicity triggered by its lead drug can be reversed, the FDA has lifted the full hold placed on its lead–and only–cancer drug. And investors responded enthusiastically to the biotech’s return to the clinic, boosting shares by 35% in premarket trading.
Fast-growing R&D services outfit WuXi PharmaTech is marching ahead with plans to wrap a $250 million venture fund aimed at U.S. and China life sciences companies. WuXi filed documents with the SEC last week outlining the goal for WuXi Healthcare Ventures Fund II, which it’s already made a $50 million anchor investment in. …read more […]